Form 4: Enliven Therapeutics CFO Exercises Stock Options and Sells Shares Under Pre-Arranged Trading Plan

Enliven Therapeutics' Chief Financial Officer, Benjamin Hohl, exercised stock options and subsequently sold the acquired common stock on May 27, 2025, as part of a pre-established Rule 10b5-1 trading plan.

Summary

• Benjamin Hohl, the Chief Financial Officer of Enliven Therapeutics, Inc. (ELVN), reported transactions on May 27, 2025, involving the company's common stock.
• Mr. Hohl exercised stock options to acquire 3,250 shares of common stock at an exercise price of $2.48 per share.
• Concurrently, he sold 3,250 shares of common stock at a weighted average sale price of $16.1826 per share.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Hohl on June 26, 2023.
• Following these reported transactions, Mr. Hohl's direct beneficial ownership of common stock is 23,000 shares, and he holds 122,056 stock options.
• The original stock option grant, from which these shares were exercised, was for 262,120 shares, with one-fourth vesting on August 2, 2022, and the remainder vesting in 36 equal monthly installments thereafter.

Sentiment

Score: 7

Explanation: The filing reports a routine insider transaction (option exercise and sale) executed under a pre-established Rule 10b5-1 trading plan, which is generally viewed neutrally or slightly positively as it indicates planned, not opportunistic, trading. The significant difference between exercise and sale price indicates a profitable transaction for the insider.

Positives

• The transactions were conducted under a Rule 10b5-1 trading plan, indicating they were pre-scheduled and not based on immediate, non-public information, which is generally viewed favorably for corporate governance.
• The sale price of $16.1826 per share is significantly higher than the exercise price of $2.48 per share, indicating a substantial profit for the insider on these specific transactions.

Industry Context

This Form 4 filing is a routine disclosure of an insider's equity transactions and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: Provides transparency on insider stock transactions, which can influence investor sentiment regarding management's view of the company's valuation and liquidity of insider holdings.

Key Dates

Keywords

Enliven Therapeutics, ELVN, Benjamin Hohl, CFO, Form 4, Insider Trading, Stock Options, Rule 10b5-1, Equity Sales, Beneficial Ownership